- This event has passed.
Clinical Talks: The road towards precision medicine in Sweden
November 26 @ 09:00 – 09:30 CET
On November 26, we will host Karolinska Institutet (KI) Professor Richard Rosenquist Brandell. In addition to his academic research and clinical work, he also co-founded the Genomic Medicine Sweden (GMS) initiative and serves as the Director of GMS. Richard will share his insights on Sweden’s national strategy to implement precision medicine into our healthcare environment and pave the way for the amazing potential the approach has to offer. To benefit from the sustainable advantages of tailored and efficient use of diagnostics and treatment options, Sweden needs to prepare our society for the legal challenges and infrastructures necessary to support and enable this transformation.
Richard Rosenquist Brandell, MD, PhD, is Professor of Clinical Genetics at Karolinska Institutet, Senior Physician at Karolinska University Hospital and director of Genomic Medicine Sweden, a national infrastructure for implementation of precision medicine. He obtained his MD degree in 1996, and later his PhD in Medicine in 1998, from Umeå University. In 2000 Richard joined Uppsala University Hospital (“Akademiska Sjukhuset”) and in 2007 became a Professor at the Department of Immunology, Genetics and Pathology, Uppsala University. In April 2017, he relocated to the Karolinska University Hospital as a Senior Physician and Professor. Richard’s work focuses on hematological malignancies and utilizing high-throughput sequencing technologies, his team has identified novel prognostic and predictive biomarkers that have significantly improved patient risk-stratification. Dr Rosenquist Brandell is also a member of the Nobel Assembly at Karolinska Institutet.
Genomic Medicine Sweden (GMS) started as a bottom-up initiative within the national Clinical Genomics Platform (previously named the Diagnostics Development platform) at the Swedish Science for Life Laboratory (SciLifeLab). In 2017 and 2018 discussions with funding agencies, decision-makers, healthcare providers, patient organisations, universities, and industry led to the founding of GMS as a national venture. GMS strategic mission is to foster collaboration between healthcare providers, academia, patient organizations and industry and realize precision medicine by effectively utilizing the rapidly advancing sequencing technologies to provide the highest standards of genomic testing in routine clinical care throughout Sweden.